Search Results 1351-1360 of 3915 for Solid
Prior solid organ or allogeneic BM transplantation, except for AML cohorts if at least 3 months since allogeneic HSCT, not receiving immunosuppressive ...
Trimethoprim-sulfamethoxazole Graded Administration in Oncology, Hematopoietic Stem Cell Transplant, and Solid Organ Transplant Patients with a History of ...
Measurable disease by any imaging modality as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in at least one site not previously ...
... Solid Tumors version 1.1 (RECIST 1.1) after initial treatment. Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter ...
Participation eligibility · Autofusion (solid arthrodesis) determined radiographically (CT); · Totally collapsed disc, or; · Vertebral body that cannot be ...
... Solid Tumors v1.1 – GIST-specific (mRECIST). Also, to compare the overall ... This Phase 1/2 study will enroll patients with various advanced solid tumors.
A Study of HFB200301 in Adult Patients With Advanced Solid Tumors. Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study ...
Patient has measurable NSCLC disease, as per the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). Metastatic lesions in CNS or in brain ...
Patients who previously received a solid organ transplant, other than those who previously received an orthotopic liver transplantation (OLT) as primary ...
Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.